{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/AVTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T01:28:23.155Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3068,"canonical_name":"Avalo Therapeutics, Inc.","cik":"0001534120","uei":null,"lei":null,"duns":null,"ticker":"AVTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":84,"clinical":1},"count":85,"timeline":[{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001534120/4/0001677036-26-000009","accession_number":"0001677036-26-000009","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001534120/4/0001707797-26-000017","accession_number":"0001707797-26-000017","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-10-02","url_slug":"/sec/cik-0001534120/4/0002063957-26-000009","accession_number":"0002063957-26-000009","importance":30},{"ts":"2026-09-18","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-09-18","url_slug":"/sec/cik-0001534120/4/0001810417-26-000023","accession_number":"0001810417-26-000023","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-09-11","url_slug":"/sec/cik-0001534120/4/0001810417-26-000021","accession_number":"0001810417-26-000021","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Sullivan Christopher Ryan","title":"Chief Financial Officer","shares":10185,"price_per_share":17.6197,"usd_value":179457,"security_title":"Common Stock","importance":35.1794566445},{"ts":"2026-09-10","kind":"sec.insider.m","reporter":"Sullivan Christopher Ryan","title":"Chief Financial Officer","shares":10185,"price_per_share":8.04,"usd_value":81887,"security_title":"Common Stock","importance":15.0818874},{"ts":"2026-09-01","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-09-01","url_slug":"/sec/cik-0001534120/4/0001918845-26-000031","accession_number":"0001918845-26-000031","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-08-19","url_slug":"/sec/cik-0001534120/4/0001810417-26-000019","accession_number":"0001810417-26-000019","importance":30},{"ts":"2026-08-19","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-08-19","url_slug":"/sec/cik-0001534120/4/0001918845-26-000029","accession_number":"0001918845-26-000029","importance":30},{"ts":"2026-08-18","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-18","url_slug":"/sec/cik-0001534120/144/0001950047-26-008317","accession_number":"0001950047-26-008317","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001534120/144/0001950047-26-008220","accession_number":"0001950047-26-008220","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001534120/144/0001950047-26-008273","accession_number":"0001950047-26-008273","importance":30},{"ts":"2026-08-17","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-17","url_slug":"/sec/cik-0001534120/144/0001950047-26-008276","accession_number":"0001950047-26-008276","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000902664-26-003460","accession_number":"0000902664-26-003460","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000921895-26-002164","accession_number":"0000921895-26-002164","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001172661-26-003475","accession_number":"0001172661-26-003475","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001727492-26-000021","accession_number":"0001727492-26-000021","importance":30},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001897612-26-000606","accession_number":"0001897612-26-000606","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-13","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001011438-26-000509","accession_number":"0001011438-26-000509","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001534120/4/0001918845-26-000026","accession_number":"0001918845-26-000026","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001534120/4/0002047607-26-000008","accession_number":"0002047607-26-000008","importance":30},{"ts":"2026-08-11","kind":"sec.form144","reporter":"JENNIFER RILEY","title":"Officer","shares":2655,"usd_value":52012,"security_title":"Common","approx_sale_date":"2026-08-11","accession_number":"0001950047-26-007948","importance":40.01040245},{"ts":"2026-08-11","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001534120/144/0001950047-26-007948","accession_number":"0001950047-26-007948","importance":30},{"ts":"2026-08-10","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-08-10","url_slug":"/sec/cik-0001534120/144/0001950047-26-007908","accession_number":"0001950047-26-007908","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001534120/schedule-13g/0000093751-26-000415","accession_number":"0000093751-26-000415","importance":55},{"ts":"2026-08-07","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000315066-26-002249","accession_number":"0000315066-26-002249","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Avalo Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001534120/10-q/0001534120-26-000049","accession_number":"0001534120-26-000049","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Avalo Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001534120/8-k/0001534120-26-000048","accession_number":"0001534120-26-000048","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000315066-26-001940","accession_number":"0000315066-26-001940","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001534120/4/0001918845-26-000024","accession_number":"0001918845-26-000024","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"424B3","title":"424B3 — Avalo Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0001534120/424b3/0001104659-26-087573","accession_number":"0001104659-26-087573","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Avalo Therapeutics, Inc. — 2026-07-28","url_slug":"/sec/cik-0001534120/effect/9999999995-26-002480","accession_number":"9999999995-26-002480","importance":30},{"ts":"2026-07-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-07-27","url_slug":"/sec/cik-0001534120/schedule-13g/0002012383-26-002194","accession_number":"0002012383-26-002194","importance":55},{"ts":"2026-07-27","kind":"sec.insider.s","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1000,"price_per_share":20,"usd_value":20000,"security_title":"Common Stock","importance":35.02},{"ts":"2026-07-27","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1000,"price_per_share":12.65,"usd_value":12650,"security_title":"Common Stock","importance":15.01265},{"ts":"2026-07-17","kind":"sec.filing","form_type":"S-3","title":"S-3 — Avalo Therapeutics, Inc. — 2026-07-17","url_slug":"/sec/cik-0001534120/s-3/0001104659-26-084609","accession_number":"0001104659-26-084609","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001534120/4/0001677036-26-000006","accession_number":"0001677036-26-000006","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001534120/4/0001707797-26-000014","accession_number":"0001707797-26-000014","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001534120/4/0001918845-26-000022","accession_number":"0001918845-26-000022","importance":30},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001534120/4/0002063957-26-000007","accession_number":"0002063957-26-000007","importance":30},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":4654,"price_per_share":20,"usd_value":93080,"security_title":"Common Stock","importance":35.09308},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":2875,"price_per_share":12.65,"usd_value":36369,"security_title":"Common Stock","importance":15.03636875},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1779,"price_per_share":8.04,"usd_value":14303,"security_title":"Common Stock","importance":15.01430316},{"ts":"2026-06-25","kind":"sec.filing","form_type":"3","title":"3 — Avalo Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001534120/3/0002063957-26-000004","accession_number":"0002063957-26-000004","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001534120/4/0001918845-26-000020","accession_number":"0001918845-26-000020","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-25","url_slug":"/sec/cik-0001534120/4/0002063957-26-000005","accession_number":"0002063957-26-000005","importance":30},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1450,"price_per_share":18,"usd_value":26100,"security_title":"Common Stock","importance":35.0261},{"ts":"2026-06-23","kind":"sec.filing","form_type":"8-K","title":"8-K — Avalo Therapeutics, Inc. — 2026-06-23","url_slug":"/sec/cik-0001534120/8-k/0001534120-26-000044","accession_number":"0001534120-26-000044","importance":35},{"ts":"2026-06-23","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1450,"price_per_share":8.04,"usd_value":11658,"security_title":"Common Stock","importance":15.011658},{"ts":"2026-06-18","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-06-18","url_slug":"/sec/cik-0001534120/schedule-13g/0001831942-26-000029","accession_number":"0001831942-26-000029","importance":55},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — Avalo Therapeutics, Inc. — 2026-06-16","url_slug":"/sec/cik-0001534120/8-k/0001534120-26-000042","accession_number":"0001534120-26-000042","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Avalo Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001534120/8-k/0001534120-26-000040","accession_number":"0001534120-26-000040","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001534120/4/0001677896-26-000008","accession_number":"0001677896-26-000008","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001534120/4/0001810417-26-000016","accession_number":"0001810417-26-000016","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001534120/4/0001918845-26-000018","accession_number":"0001918845-26-000018","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001534120/4/0002047607-26-000006","accession_number":"0002047607-26-000006","importance":30},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":1084,"price_per_share":13.1,"usd_value":14200,"security_title":"Common Stock","importance":15.0142004},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"VARKI PAUL","title":"Chief Legal Officer","shares":1081,"price_per_share":13.1,"usd_value":14161,"security_title":"Common Stock","importance":15.0141611},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Riley Jennifer","title":"Chief Strategy Officer","shares":588,"price_per_share":13.1,"usd_value":7703,"security_title":"Common Stock","importance":15.0077028},{"ts":"2026-06-10","kind":"sec.insider.f","reporter":"Sullivan Christopher Ryan","title":"Chief Financial Officer","shares":138,"price_per_share":13.1,"usd_value":1808,"security_title":"Common Stock","importance":15.0018078},{"ts":"2026-06-05","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-06-05","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000315066-26-001408","accession_number":"0000315066-26-001408","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001534120/4/0001677036-26-000004","accession_number":"0001677036-26-000004","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001534120/4/0001707797-26-000008","accession_number":"0001707797-26-000008","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001534120/4/0001862734-26-000004","accession_number":"0001862734-26-000004","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0001534120/4/0002017156-26-000004","accession_number":"0002017156-26-000004","importance":30},{"ts":"2026-06-02","kind":"sec.form144","reporter":"JONATHAN GOLDMAN","title":"Director","shares":42833,"usd_value":616226,"security_title":"Common","approx_sale_date":"2026-06-02","accession_number":"0001950047-26-005476","importance":40.123245228},{"ts":"2026-06-02","kind":"sec.filing","form_type":"144","title":"144 — Avalo Therapeutics, Inc. — 2026-06-02","url_slug":"/sec/cik-0001534120/144/0001950047-26-005476","accession_number":"0001950047-26-005476","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-06-01","url_slug":"/sec/cik-0001534120/4/0001918845-26-000016","accession_number":"0001918845-26-000016","importance":30},{"ts":"2026-05-28","kind":"sec.insider.s","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":679,"price_per_share":16,"usd_value":10864,"security_title":"Common Stock","importance":35.010864},{"ts":"2026-05-28","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":679,"price_per_share":8.04,"usd_value":5459,"security_title":"Common Stock","importance":15.00545916},{"ts":"2026-05-19","kind":"sec.filing","form_type":"4","title":"4 — Avalo Therapeutics, Inc. — 2026-05-19","url_slug":"/sec/cik-0001534120/4/0001918845-26-000012","accession_number":"0001918845-26-000012","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001534120/schedule-13g/0000902664-26-002462","accession_number":"0000902664-26-002462","importance":55},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001534120/schedule-13g/0001897612-26-000487","accession_number":"0001897612-26-000487","importance":55},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":3000,"price_per_share":18.76,"usd_value":56280,"security_title":"Common Stock","importance":35.05628},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001727492-26-000008","accession_number":"0001727492-26-000008","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000921895-26-001385","accession_number":"0000921895-26-001385","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-05-15","url_slug":"/sec/cik-0001534120/schedule-13g-a/0000935836-26-000282","accession_number":"0000935836-26-000282","importance":30},{"ts":"2026-05-15","kind":"sec.insider.m","reporter":"Doyle Mittie","title":"Chief Medical Officer","shares":3000,"price_per_share":12.65,"usd_value":37950,"security_title":"Common Stock","importance":15.03795},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Avalo Therapeutics, Inc. — 2026-05-14","url_slug":"/sec/cik-0001534120/schedule-13g-a/0001011438-26-000312","accession_number":"0001011438-26-000312","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Avalo Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001534120/10-q/0001534120-26-000033","accession_number":"0001534120-26-000033","importance":45},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Avalo Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001534120/8-k/0001534120-26-000032","accession_number":"0001534120-26-000032","importance":35},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Avalo Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001534120/schedule-13g/0001193125-26-220002","accession_number":"0001193125-26-220002","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"Avalo Therapeutics, Inc.","shares":3017120,"percent_of_class":7.9,"security_title":"SCHEDULE 13G","accession_number":"0001193125-26-220002","excerpt":null,"importance":55},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Avalo Therapeutics, Inc.","title":"A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06603077","excerpt":"[\"Hidradenitis Suppurativa\"]","importance":45}]}